Efecto en el manejo de los niveles de hemoglobina glicosilada de la metformina vs liraglutida inyectable vs semaglutida inyectable en pacientes obesos (IMC ≥ 30) de un programa de manejo de síndrome metabólico en una clínica de Maicao (la Guajira, Co) durante los años 2022 a 2023
Cargando...
Fecha
2024
Autores
Herrera Díaz, Luis Carlos
Quiroz Barraza, Jairo José
Título de la revista
ISSN de la revista
Título del volumen
Editor
Ediciones Universidad Simón Bolívar
Facultad de Ciencias de la Salud
Facultad de Ciencias de la Salud
Resumen
La obesidad es un factor de riesgo crítico para enfermedades metabólicas y cardiovasculares, exacerbando el síndrome metabólico en poblaciones vulnerables. En respuesta a esta problemática, los agonistas GLP-1 (liraglutida y semaglutida) y la metformina han sido estudiados ampliamente por su potencial para mejorar los niveles de hemoglobina glicosilada (HbA1c), peso, presión arterial y perfil lipídico en pacientes obesos. Objetivo: Comparar del efecto Metformina vs Liraglutida Inyectable vs Semaglutida Inyectable en pacientes Obesos (IMC ≥ 30) de un Programa de Manejo de Síndrome Metabólico en una Clínica de Maicao (La Guajira, CO) durante los años 2022 a 2023. Metodología: Se realizó un estudio observacional, analítico y de cohorte longitudinal con 45 pacientes obesos (IMC ≥ 30) tratados con liraglutida, semaglutida o metformina durante el período de 2022-2023. Se analizaron datos de HbA1c, IMC, presión arterial (PAS y PAD) y perfil lipídico (colesterol total, HDL-C y LDL-C) mediante análisis de varianza (ANOVA) para muestras pareadas e independientes. Resultados: En este estudio con 45 pacientes obesos (60% mujeres, edad promedio 53.1 años), no hubo diferencias significativas entre sexos en PAS, PAD, IMC, ni HbA1C. Los hombres presentaron mayor hipertensión (72%) y uso de liraglutida (p=0.04). Entre los tratamientos (liraglutida, metformina y semaglutida), no se hallaron diferencias significativas en parámetros basales. La PAS disminuyó en todos los grupos, siendo mayor en liraglutida y semaglutida; sin embargo, la PAD solo mejoró significativamente con metformina. El grupo de semaglutida mostró la mayor reducción en IMC (p<0.001) y HbA1C (-1.0%), además de una mejora significativa en HDL-C y reducción en colesterol total. Conclusión: Los agonistas GLP-1, especialmente la semaglutida, demostraron mayor efectividad en el control de HbA1c y en la reducción de IMC en pacientes obesos, además de ofrecer beneficios adicionales en el perfil lipídico. Estos hallazgos respaldan el uso de semaglutida y liraglutida como opciones prometedoras en el manejo integral del síndrome metabólico en pacientes con obesidad.
Obesity is a critical risk factor for metabolic and cardiovascular diseases, exacerbating metabolic syndrome in vulnerable populations. In response to this issue, GLP-1 agonists (liraglutide and semaglutide) and metformin have been widely studied for their potential to improve hemoglobin A1c (HbA1c) levels, weight, blood pressure, and lipid profile in obese patients. Objective: To compare the effect of Metformin vs. Injectable Liraglutide vs. Injectable Semaglutide in obese patients (BMI ≥ 30) enrolled in a Metabolic Syndrome Management Program at a clinic in Maicao (La Guajira, CO) from 2022 to 2023. Methodology: An observational, analytical, and longitudinal cohort study was conducted with 45 obese patients (BMI ≥ 30) treated with liraglutide, semaglutide, or metformin during the 2022-2023 period. Data on HbA1c, BMI, blood pressure (SBP and DBP), and lipid profile (total cholesterol, HDL-C, and LDL-C) were analyzed using analysis of variance (ANOVA) for paired and independent samples. Results: In this study with 45 obese patients (60% women, mean age 53.1 years), there were no significant differences between sexes in SBP, DBP, BMI, or HbA1c. Men presented with higher rates of hypertension (72%) and liraglutide use (p=0.04). Among treatments (liraglutide, metformin, and semaglutide), no significant differences were found in baseline parameters. SBP decreased in all groups, with a greater reduction in liraglutide and semaglutide; however, DBP only significantly improved with metformin. The semaglutide group showed the largest reduction in BMI (p<0.001) and HbA1c (-1.0%), as well as a significant increase in HDL-C and reduction in total cholesterol. Conclusion: GLP-1 agonists, especially semaglutide, demonstrated greater effectiveness in controlling HbA1c and reducing BMI in obese patients, in addition to providing additional benefits in lipid profile. These findings support the use of semaglutide and liraglutide as promising options for comprehensive management of metabolic syndrome in obese patients.
Obesity is a critical risk factor for metabolic and cardiovascular diseases, exacerbating metabolic syndrome in vulnerable populations. In response to this issue, GLP-1 agonists (liraglutide and semaglutide) and metformin have been widely studied for their potential to improve hemoglobin A1c (HbA1c) levels, weight, blood pressure, and lipid profile in obese patients. Objective: To compare the effect of Metformin vs. Injectable Liraglutide vs. Injectable Semaglutide in obese patients (BMI ≥ 30) enrolled in a Metabolic Syndrome Management Program at a clinic in Maicao (La Guajira, CO) from 2022 to 2023. Methodology: An observational, analytical, and longitudinal cohort study was conducted with 45 obese patients (BMI ≥ 30) treated with liraglutide, semaglutide, or metformin during the 2022-2023 period. Data on HbA1c, BMI, blood pressure (SBP and DBP), and lipid profile (total cholesterol, HDL-C, and LDL-C) were analyzed using analysis of variance (ANOVA) for paired and independent samples. Results: In this study with 45 obese patients (60% women, mean age 53.1 years), there were no significant differences between sexes in SBP, DBP, BMI, or HbA1c. Men presented with higher rates of hypertension (72%) and liraglutide use (p=0.04). Among treatments (liraglutide, metformin, and semaglutide), no significant differences were found in baseline parameters. SBP decreased in all groups, with a greater reduction in liraglutide and semaglutide; however, DBP only significantly improved with metformin. The semaglutide group showed the largest reduction in BMI (p<0.001) and HbA1c (-1.0%), as well as a significant increase in HDL-C and reduction in total cholesterol. Conclusion: GLP-1 agonists, especially semaglutide, demonstrated greater effectiveness in controlling HbA1c and reducing BMI in obese patients, in addition to providing additional benefits in lipid profile. These findings support the use of semaglutide and liraglutide as promising options for comprehensive management of metabolic syndrome in obese patients.
Descripción
Palabras clave
Obesidad, Síndrome metabólico, Hemoglobina glicosilada (HbA1c), Liraglutida, Semaglutida, Metformina, Índice de masa corporal (IMC), Perfil lipídico, Presión arterial